Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma

For patients with Merkel cell carcinoma (MCC) who are refractory to immune checkpoint inhibition (ICI), treatment options are limited. Few cases of MCCs have been reported to show responses to peptide receptor radionuclide therapy (PRRT). A combination of PRRT and ICI has not been reported in MCC to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Nuclear Medicine 2022-03, Vol.63 (3), p.396-398
Hauptverfasser:	Ferdinandus, Justin, Fendler, Wolfgang P, Lueckerath, Katharina, Berliner, Christoph, Kurzidem, Sabine, Hadaschik, Eva, Klode, Joachim, Zimmer, Lisa, Livingstone, Elisabeth, Schadendorf, Dirk, Herrmann, Ken, Becker, Juergen C, Ugurel, Selma
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Merkel Cell - drug therapy Carcinoma, Merkel Cell - etiology Carcinoma, Renal Cell - drug therapy Combined treatment Female Humans Immune checkpoint inhibitors Immunotherapy Ipilimumab - therapeutic use Kidney Neoplasms - pathology Male Metastases Metastasis Monoclonal antibodies Nausea Nivolumab - therapeutic use Patients Peptides Prospective Studies Radiation therapy Radioisotopes Radioisotopes - therapeutic use Receptors Receptors, Peptide - therapeutic use Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - therapy Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!